Evidence map›Paper›PMID 34066376›Full record

ArticleVaccines2021

Early and Solid Protection Afforded by the Thiverval Vaccine Provides Novel Vaccination Alternatives Against Classical Swine Fever Virus.

Yaneysis Lamothe-Reyes, José Alejandro Bohórquez, Miaomiao Wang, Mònica Alberch, Marta Pérez-Simó, Rosa Rosell, Llilianne Ganges

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Removal of the EJournal of virology · 2022
    Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yaneysis Lamothe-ReyesOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.ORCID 0000-0002-7012-2228
José Alejandro BohórquezOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.ORCID 0000-0002-6715-1757
Miaomiao WangOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.
Mònica AlberchOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.
Marta Pérez-SimóOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.
Rosa RosellOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.
Llilianne GangesOIE Reference Laboratory for Classical Swine Fever, Institut de Recerca i Tecnologia Agroalimentàries, Centre de Recerca en Sanitat Animal IRTA-CReSA, 08193 Barcelona, Spain.ORCID 0000-0002-8644-3560
Centre de Recerca en Sanitat Animal · ESGeneralitat de Catalunya · ESUniversity of Concepción · CL

Funding

ANID (ex-CONICYT) PFCHA Doctorado Nacional/2017-21170713CEVA Santé Animale, France Thiverval vaccineCSC scholarship (2017), from the Chinese government M.W. has a pre-doctoral fellowship, CSC scholarship (2017)Ministerio de Ciencia e Innovación, from Spanish government J.A.B has a pre-doctoral fellowship, FPI 2016Ministerio de Ciencia, e Innovación from the Spanish government RTI2018-100887-B-I00
6 · The paper itself

Abstract

Classical swine fever virus (CSFV) remains a challenge for the porcine industry. Inefficient vaccination programs in some endemic areas may have contributed to the emergence of low and moderate virulence CSFV variants. This work aimed to expand and update the information about the safety and efficacy of the CSFV Thiverval-strain vaccine. Two groups of pigs were vaccinated, and a contact and control groups were also included. Animals were challenged with a highly virulent CSFV strain at 21- or 5-days post vaccination (dpv). The vaccine induced rapid and strong IFN-α response, mainly in the 5-day immunized group, and no vaccine virus transmission was detected. Vaccinated pigs showed humoral response against CSFV E2 and E

Indexed as

challengeclinical protectionCSFVimmune responseThiverval strainvaccinationvaccinevirological protection

Identifiers

PMID34066376
PMCPMC8148177
OpenAlexW3158511016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.